On May 28, 2025 Invectys, Inc., a clinical-stage biotechnology company pioneering novel cancer immunotherapies, reported that MD Anderson Investigators Drs. Samer Srour and Aung Naing will present a Trial-in-Progress poster at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 30–June 3 in Chicago, Illinois (Press release, Invectys, MAY 28, 2025, View Source [SID1234653612]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will detail the ongoing Phase 1/2a clinical trial evaluating IVS-3001, Invectys’ first-in-human chimeric antigen receptor (CAR) T-cell therapy targeting HLA-G, a non-classical MHC class I molecule overexpressed in various solid tumors. HLA-G functions as a powerful immune checkpoint, enabling tumor cells to evade immune surveillance. By engineering CAR T cells to recognize and eliminate HLA-G–expressing cancer cells, IVS-3001 aims to restore the immune system’s ability to combat tumors.
Presentation Details:
Abstract Title: Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress
Abstract Number: TPS2679
Session: Developmental Therapeutics—Immunotherapy
Session Type: Poster Session
Poster Board Number: 320b
Date and Time: Monday, June 2, 2025, 1:30 PM – 4:30 PM CDT
Location: McCormick Place Convention Center, Chicago, IL
The Phase 1/2a trial is designed to assess the safety, tolerability, and preliminary efficacy of IVS-3001 in patients with advanced solid tumors expressing HLA-G. The study also aims to evaluate the therapy’s pharmacokinetics and immunogenicity.
"We are excited to share our progress on IVS-3001 at ASCO (Free ASCO Whitepaper) 2025. Patients with solid tumors have profound unmet clinical need. HLA-G is an especially exciting target for cell therapy, as it is both a widely expressed tumor marker and a potent immune checkpoint. Thus, HLA-G directed therapies have the potential to treat a vast variety of solid tumors." said Dr. Jake Kushner, CEO of Invectys. "This study represents a key step forward in our mission to develop innovative immunotherapies that address unmet needs in oncology."